Featured Opinions
Secrets of success for a value-based KAM model in Pharma
Value based selling is (finally) coming to pharma. A few forward-thinking pharmaceutical companies are trying this new approach to Key Account Management, calling it Value Based Engagements or Partnerships for Healthcare Value (PHV). But what does it take to it pull off? Pharmaceutical...
Where does healthcare marketing go from here?
Where does healthcare marketing go from here?
Mals Musings: Please regulate us now!
The pharma industry cannot operate without public trust, but our trust accounts are dangerously depleted. The rescue package: more regulation.
Mals Musings: Improving lives or improving profits?
/The public has turned on the financial sector for caring more about profits than about people. Is the pharma industry next?/
Pharma reps: scientists or salespeople?
by Jim Usry
What do household appliances and H2 antagonists have in common? Both need to be sold with a combination of knowledge and passion.
GSK to make a movie but not for promotional purposes (or so they say)
If America is at war with obesity, then obesity is winning.
Welcome to 2010. where might pharma and healthcare marketers focus learning? (free eBook)
Inspired by Alvin Toffler's quote: "/The illiterate of the 21st century will not be those who cannot read or write, but those who cannot learn, unlearn, and relearn/," we asked 12 leading bl
======== THE APPEAL: STOP SELLING DRUGS! ===================================== Across the world many pharma still are trying to sell drugs in a desperate attempt to keep and stick to the past instead of actively pursuing the *c*
Pharma & Social Media: Best Strategic Learning Investment for 2010
by Phil Baumann
This is a re-post from PhilBaumann.com [1]. It is being published here so that eyeforpharma readers can read and comment. Ellen Hoenig Carlson compiled an ebook of insights and suggestions for helping the pharmaceutical and other health care industries adapt to 21st Century challenges and...
Key trends in the neurodegenerative disease market
by Anonymous (not verified)
Although there are dozens of neurodegenerative diseases, most are rare or are themselves symptoms of other diseases or illnesses such as stroke, alco
2010 outlook: 10 ways to win with patients and improve DTC efforts
[Full article: 2010 Outlook: Doom and Gloom For DTC? [1] [1] http://www.dtcperspectives.com/content/editor/files/Dec2009/2010Outlook.pdf
by Anonymous (not verified)
Most pharma companies have embarked on key account management (KAM) initiatives in one way or another. But building a true KAM competency can be a costly proposition. And in an environment where so many organizations are cutting costs, pharmaceutical executives need to ask some tough questions: How exactly do we create new value through KAM? Are we there yet?